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Abstract
Background and Aims: The lung large-cell neuroendocrine carcinoma (LCNEC) is
a very rare aggressive neuroendocrine tumor with a high propensity to metastasize
and very poor prognosis. We report an atypical presentation of lung LCNEC was
diagnosed from a metastatic nodule on the breast.
Methods: Our patient is a 59-years-old woman that presented in March 2014 non-
productive cough. A CT scan showed multiple brain, lung, adrenal gland and liver
secondary lesions; moreover, it revealed a breast right nodule near the chest meas-
uring 1.8 cm. The breast nodule and lung lesions were biopsied and their histology
and molecular diagnosis were LCNEC of the lung. To our knowledge, this is the first
documented case of breast metastasis from LCNEC of the lung.
Results: Furthermore, breast metastasis from extramammary malignancy is uncom-
mon and its diagnosis is difficult but important for proper management and pre-
diction of prognosis. Therefore, a careful clinical history with a thorough clinical
examination is needed to make the correct diagnosis. Moreover, metastasis to the
breast should be considered in any patient with a known primary malignant tumor
history who presents with a breast lump. Anyhow, pathological examination should
be performed to differentiate the primary breast cancer frommetastatic tumor.
Conclusion: Therefore, an accurate diagnosis of breast metastases may not only
avoid unnecessary breast resection, more importantly it is crucial to determine an
appropriate and systemic treatment.
Please cite this paper as: Papa A, Rossi L, Verrico M, Di Cristofano C, Moretti V,
Strudel M, Zoratto F, Minozzi M, Tomao S. Breast metastasis and lung large-cell
neuroendocrine carcinoma: first clinical observation. Clin Respir J 2017; 11: 574-
578. DOI:10.1111/crj.12385.
Background
Neuroendocrine tumor of the lung is classified into
four subtypes according to the recent World Health
Organization Classification: typical carcinoid, atypical
carcinoid, small cell carcinoma, and large-cell neuroen-
docrine carcinoma (LCNEC) (1). LCNEC is now
recognized as a histologically high-grade nonsmall cell
carcinoma by WHO (2).
The diagnosis of LCNEC is based on recognition of
both neuroendocrine morphology (organoid pattern)
and the immunohistochemical demonstration of spe-
cific neuroendocrine markers (2), such as
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chromogranin, synaptophysin, and neural cell adhe-
sion molecule, also known as CD56. To confirm the
neuroendocrine origin in the tumor cells, at least one
such marker must be positive.
The lung LCNEC is an aggressive and rare neoplasm
and one of the most challenging diseases to diagnose
and treat. It accounts for approximately 1.6%–3.1% of
all lung cancer (3) categorized as a variant of large cell
carcinoma. The lung LCNEC has a distant metatasize
rate of 65% (4) and poor prognosis even in early
stages, with survival rates similar to small-cell lung
cancer (SCLC) (5). The life expectancy of stage IV lung
LCNEC with distant metastasis was estimated at
around 6 months (6).
In this article, we present an atypical case of LCNEC
with metastasis to the brain, liver, and breast.
The clinically observed rate of breast metastases from
extramammary malignancies is rare, ranging from 0.5%
to 1.3%, due to the late appearance of extramammary
malignancies in the course of malignant disease (7).
Typically, most patients are in a preterminal condi-
tion with systemic metastases outside the breast (8).
In literature, 31 reported cases of non-small-cell
lung carcinoma (NSCLC) metastasized to the breast
were identified, along with eight cases of small-cell
lung carcinoma (9).
Furthermore, the most common sources of extra-
mammary metastases to the breast are lymphomas/
leukemias and melanomas. Some of the less com-
mon sources include carcinomas of the lung, ovary,
and stomach, and infrequently, carcinoid tumors,
hypernephromas, carcinomas of the liver, tonsil,
pleura, pancreas, cervix, perineum, endometrium
and bladder (10). Usually, breast metastasis indicates
disseminated metastatic disease and carries a poor
prognosis (11).
Due to the fact that patients with lung LCNEC are
less likely to present with pulmonary symptoms such
as cough, hemoptysis or postobstructive pneumonia
(12), the early detection and diagnosis represent hard
challenges.
Case report
We report the rare case of a 59-years-old female patient
that presented nonproductive cough in March 2014.
Pertinent social history includes 10 cigarettes/day from
40 years history of tobacco smoking. In May 2014, she
had a bronchopneumonia episode and she was hospi-
talized. During hospitalization a chest X-ray and an
ultrasound abdomen were performed. Ultrasound
(US) revealed liver lesions suspected to be metastatic.
Figure 1. CT scan showing brain lesions (A, B), middle lobe lung lesion and atelectasis (C), liver lesions (D) and right breast
nodule (E).
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The patient came to our observation on July 2014 and
she had a total body CT scan (Fig. 1) and bone-scan.
The CT scan showed multiple secondary brain lesions
(Fig. 1A, B), a consolidation of the right lung meas-
uring 3.9 cm, due to a middle lobe lesion associated
with atelectasis (Fig. 1C); hilar and mediastinal lymph-
adenopathy were also described, as well as multiple
focal liver metastases (Fig. 1D) and two lesions, respec-
tively, to the left and right adrenal gland. Moreover, CT
scan revealed a breast right nodule near the chest,
measuring 1.8 cm (Fig. 1E).
A biopsy of the breast nodule and a biopsy of the
lung lesion were performed.
Morphologically, both samples show tumor cells
arranged in nests and cords solids, often with trabecu-
lar growth pattern. Neoplastic cells are large with
rounded nuclei, often irregular and with moderate
eosinophilic cytoplasm. Mitotic counts exceed 10 per
10 high power field (HPF). These features are evident
in the pathology report slides (Fig. 2A, hematoxylin/
eosin). The positive stain of synaptophysin (Fig. 2B)
and chromogranine A (Fig. 2C) confirmed the neuro-
endocrine origin. The neoplastic cells of breast’s nodule
were positive also for thyroid transcription factor 1
(TTF-1) (Fig. 2D).
Subsequently, patient received three cycles of cisp-
latin–etoposide and on October 2014, CT scan revealed
progression disease. A second-line treatment with top-
otecan was performed; unluckily a CT scan evaluation
after 2 months of treatment showed a new progression
disease. Considering progression and clinical condi-
tions worsening, the patient underwent best supportive
care; after 4 weeks the death occurred.
Discussion
LCNEC of the lung is a variant of a large cell carci-
noma which exhibits neuroendocrine architectural fea-
tures and immunohistochemical or ultrastructural
evidence of neuroendocrine differentiation (4, 5). It is
one of the most challenging diseases to diagnose and
treat. The incidence is approximately 1.6%–3.1% of all
lung cancer (2).
Particularly, the diagnosis of LCNEC is defined as:
microscopical neuroendocrine morphology, large
tumor cells, low nuclear-cytoplasmic coarse chromatin
and a lot of nucleoli, mitotic rate more than 10 mitoses
per 10 high power fields, tumor necrosis; immunohis-
tochemical positivity to Cromogranine A and/or other
specifical neuroendocrinal markers (13).
Figure 2. Pathology report slides: hematoxylin/eosin slide (A), positive stain of synaptophysin (B), positive stain of
chromogranine A (C), breast’s nodule cells, positive for TTF-1 (D).
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Breast metastasis from extramammary malignancy is
uncommon and often presents hard diagnostic chal-
lenges. The overall incidence of extramammary metas-
tasis to the breast is 0.2%–1.3% of all malignant breast
tumors. Patients with non-Hodgkin lymphoma, mela-
noma and carcinoma of the lung, stomach, ovary, kid-
ney and colorectum in adults and children with
rhabdomyosarcoma, have a higher risk of metastasis to
the breast (14).
Distant metastasize rate is 65% (4). In literature,
many cases revealed abnormal locations of metastases
of lung LCNEC.
In 2010, Tsimpas et al. reported a rather uncommon
metastatic case to the cauda equina and to the lumbar
spine causing foot drop (15).
In 2011, Tadashi reported a case with a man who
had quadruple carcinomas; esophageal squamous cell
carcinoma, prostatic well differentiated adenocarci-
noma, gastric moderately differentiated adenocarci-
noma and lung LCNEC diagnosed in a brain
metastasis (16).
In 2012, Shimizu et al. describes a 77-years-old man
with LCNEC of the lung and metastases from this pri-
mary cancer in prostate (17).
In 2014, Mitsuaki et al. documented the first case of
metastatic LCNEC of the lung in the scalp (18).
Also in 2014, Cai Yuan et al. elucidates the unusual
case of cutaneous metastasis site from LCNEC (19).
In this report, we describe the first documented case
of metastatic LCNEC of the lung in the breast. Any-
how, because LCNEC is rare, the optimal treatment
including chemotherapy has not been defined (20).
Usually, the most used schedule is platinum-based
chemotherapy, however, the outcome remains poor.
Recent studies showed that LCNEC responds to
cisplatin-based chemotherapy, like those used for
SCLC (21). Regarding this controversy palliative chem-
otherapy for LCNEC, Sun et al. in their study evaluated
whether advanced lung LCNEC should be treated simi-
larly to SCLC or non-small-cell lung cancer (NSCLC);
he concluded that treatment similar to SCLC is more
appropriate than NSCLC (21).
The outcome of advanced LCNEC treated with
cisplatin-etoposide doublets is poor, similar to those of
patients with advanced SCLC (22). The life expectancy
of stage IV LCNEC with distant metastasis is around 6
months (6). Furthermore, its prognosis is poor even in
early stages.
The majority of previous studies reported that
LCNEC is associated with poor survival compared to
stage-matched NSCLC, approaching the very poor
prognosis of SCLC (12, 23).
Therefore, new therapeutic options are needed.
Tyrosine kinase inhibitors (TKI) have demonstrated
greater efficacy and better tolerability than standard
chemotherapy in nonsmall-cell lung cancer harboring
epidermal growth factor receptor (EGFR) mutations
(24). The research of EGFR mutations is not per-
formed routinely on LCNEC because it is not com-
monly present in this subtype (22), like our case;
already today at least two cases of lung LCNEC positive
for EGFR mutation it has been reported in the litera-
ture, and then treated with TKI showing a good sensi-
tivity to the same. (24, 25).
In the end, the diagnosis of metastasis to the breast
from extramammary malignancies is difficult but
important for proper management and prediction of
prognosis; therefore, a careful clinical history with an
accurate clinical examination is needed to make the
correct diagnosis.
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